Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282052 | 1.00 | NPC1 (0.50) | NPC1RAB9AKDM4EPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4938668 | 0.99 | KDM4E (0.49) | NPC1RAB9AKDM4EPOLBSMN1; SMN2 | |
| SCHEMBL14282051 | 0.94 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2OPRM1OPRD1 | |
| SCHEMBL4938963 | 0.94 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL4935811 | 0.93 | L3MBTL1 (0.50) | NPC1RAB9ASMN1; SMN2OPRM1OPRD1 | |
| SCHEMBL4932792 | 0.87 | HTR2A (0.49) | RAB9AOPRM1OPRD1OPRK1ROCK2 | |
| SCHEMBL14282049 | 0.87 | HTR2A (0.49) | RAB9AOPRM1OPRD1OPRK1ROCK2 | |
| Hydrochloric Acid SCHEMBL4936765 | 0.86 | HTR2A (0.48) | RAB9AOPRM1OPRD1OPRK1ROCK2 | |
| SCHEMBL14282053 | 0.81 | NR1H4 (0.50) | NPC1RAB9ASMN1; SMN2OPRM1OPRD1 | |
| SCHEMBL4935273 | 0.81 | NR1H4 (0.50) | NPC1RAB9ASMN1; SMN2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | NPC1 652/4885RAB9A 3737/4885KDM4E 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.